Eurogentec and BD Diagnostics Finalize Molecular Diagnostic Agreements
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Eurogentec S.A. has announced finalization of two agreements with BD Diagnostics, a segment of BD (Becton, Dickinson and Company): a technology transfer and license agreement covering proprietary diagnostic manufacturing technology and a multi-year supply agreement.
Under terms of the technology transfer and license agreement, Eurogentec will convey diagnostic manufacturing technology and provide technical assistance. BD expects to apply this technology to the production of commercial molecular diagnostic kits. Under terms of the supply agreement, Eurogentec will provide molecular diagnostic kit components to BD.
“Eurogentec is extremely pleased to partner with a leading global medical technology company such as BD’’ says Eurogentec CEO Jean-Pierre Delwart, “This is a powerful indicator of increased recognition for Eurogentec’s vision and technical expertise in IVD manufacturing by commercial developers of in vitro diagnostic products. The opening of our GMP/QSR compliant clean room oligonucleotide manufacturing facilities in Europe, North America and Asia was an important strategic decision which, when coupled with our increased integration of IVD and Pharma GMP manufacturing activities, has enabled us to go beyond oligo manufacturing and offer a full range of GMP-grade molecular diagnostic kit components and services. This will further solidify our presence and market share in the rapidly growing North American, Asian and European molecular diagnostics markets.’’
“BD is committed to developing assays and platforms that improve the detection and management of infectious diseases and cancer,” said Philippe Jacon, President, BD Diagnostics – Diagnostic Systems. “Our agreements with Eurogentec reflect this commitment by seeking leading, high-quality technologies and components that help to enhance the capabilities of our products.”
Financial terms of the agreement were not disclosed.
Under terms of the technology transfer and license agreement, Eurogentec will convey diagnostic manufacturing technology and provide technical assistance. BD expects to apply this technology to the production of commercial molecular diagnostic kits. Under terms of the supply agreement, Eurogentec will provide molecular diagnostic kit components to BD.
“Eurogentec is extremely pleased to partner with a leading global medical technology company such as BD’’ says Eurogentec CEO Jean-Pierre Delwart, “This is a powerful indicator of increased recognition for Eurogentec’s vision and technical expertise in IVD manufacturing by commercial developers of in vitro diagnostic products. The opening of our GMP/QSR compliant clean room oligonucleotide manufacturing facilities in Europe, North America and Asia was an important strategic decision which, when coupled with our increased integration of IVD and Pharma GMP manufacturing activities, has enabled us to go beyond oligo manufacturing and offer a full range of GMP-grade molecular diagnostic kit components and services. This will further solidify our presence and market share in the rapidly growing North American, Asian and European molecular diagnostics markets.’’
“BD is committed to developing assays and platforms that improve the detection and management of infectious diseases and cancer,” said Philippe Jacon, President, BD Diagnostics – Diagnostic Systems. “Our agreements with Eurogentec reflect this commitment by seeking leading, high-quality technologies and components that help to enhance the capabilities of our products.”
Financial terms of the agreement were not disclosed.
